國藥現代(600420.SH):氯化鉀注射液獲得藥品補充申請批准通知書
格隆匯12月14日丨國藥現代(600420.SH)公佈,公司全資子公司國藥集團容生製藥有限公司(以下簡稱“國藥容生”)收到國家藥品監督管理局核准簽發的氯化鉀注射液(10ml:1.5g)《藥品補充申請批准通知書》。
氯化鉀注射液為臨牀常用預防和治療低鉀血癥藥物,還可用於治療洋地黃中毒所致的早搏和心律失常。氯化鉀注射液(10ml:1.5g)為國家基本藥物目錄(2018年)產品,目前國內主要生產廠商包括湖北科倫藥業有限公司、山東華魯製藥有限公司、辰欣藥業股份有限公司等。根據米內網數據庫顯示,2020年氯化鉀注射液(10ml:1.5g)在國內城市公立醫院銷售額為人民幣5312.00萬元。截至目前,國藥容生氯化鉀注射液(10ml:1.5g)項目累計研發投入約人民幣215.21萬元(未經審計)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.